Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Up 15.2% in January

Portage Biotech Inc. (NASDAQ:PRTG) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 22,800 shares, a growth of 15.2% from the January 15th total of 19,800 shares. Based on an average daily trading volume, of 653,800 shares, the short-interest ratio is presently 0.0 days. Currently, 5.2% of the company’s shares are sold short.

Portage Biotech Stock Performance

PRTG traded down $0.23 during mid-day trading on Friday, reaching $4.61. The stock had a trading volume of 7,785 shares, compared to its average volume of 129,256. The stock has a market capitalization of $4.84 million, a P/E ratio of -0.11 and a beta of 1.31. The firm’s fifty day simple moving average is $4.74 and its two-hundred day simple moving average is $4.82. Portage Biotech has a 52 week low of $2.10 and a 52 week high of $23.01.

Portage Biotech (NASDAQ:PRTG) last announced its quarterly earnings data on Tuesday, November 26th. The company reported ($1.26) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Portage Biotech stock. Sanctuary Advisors LLC purchased a new position in Portage Biotech Inc. (NASDAQ:PRTG) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 297,728 shares of the company’s stock, valued at approximately $63,000. Sanctuary Advisors LLC owned about 28.36% of Portage Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 13.36% of the company’s stock.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.